H.C. Wainwright raised the firm’s price target on Balchem to $170 from $167 and keeps a Buy rating on the shares following the Q1 report. The company reported a revenue beat with earnings in-line, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCPC:
- Balchem reports Q1 EPS $1.03 vs 94c last year
- New York Jets enter multi-year partnership with VitaCholine
- New York Jets Announce Multi-Year Partnership with VitaCholine®
- Balchem Corporation to Attend the BMO 19th Annual Global Farm to Market Conference on May 16, 2024
- BCPC Upcoming Earnings Report: What to Expect?